Evidence map›Paper›PMID 31915854›Full record

ReviewCancer immunology, immunotherapy : CII2020

Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer.

Morten Orebo Holmström, Sabrina Cordua, Vibe Skov, Lasse Kjær, Niels Pallisgaard, Christina Ellervik, Hans Carl Hasselbalch, Mads Hald Andersen

Open access · greenAbstract readReview
In one paragraph

Review in Cancer immunology, immunotherapy : CII, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Calreticulin Expression in Human Carcinomas: A Systematic Review and Meta-Analysis.Asian Pacific journal of cancer prevention : APJCP · 2023
    Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. The mechanisms of action of Plasmodium infection against cancer.Cell communication and signaling : CCS · 2021
    Review
  10. Article
  11. The Role of the RNA-Binding Protein Family MEX-3 in Tumorigenesis.International journal of molecular sciences · 2020
    Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Morten Orebo HolmströmNational Center for Cancer Immune Therapy, Herlev Hospital, Borgmester Ib Juuls Vej 25C, 5. Sal, 2730, Herlev, Denmark. holmeren1@yahoo.dk.ORCID http://orcid.org/0000-0002-3764-8578
Sabrina CorduaDepartment of Hematology, Zealand University Hospital, Roskilde, Denmark.
Vibe SkovDepartment of Hematology, Zealand University Hospital, Roskilde, Denmark.
Lasse KjærDepartment of Hematology, Zealand University Hospital, Roskilde, Denmark.
Niels PallisgaardDepartment of Surgical Pathology, Zealand University Hospital, Roskilde, Denmark.
Christina EllervikFaculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Hans Carl HasselbalchDepartment of Hematology, Zealand University Hospital, Roskilde, Denmark.
Mads Hald AndersenNational Center for Cancer Immune Therapy, Herlev Hospital, Borgmester Ib Juuls Vej 25C, 5. Sal, 2730, Herlev, Denmark.
Zealand University Hospital · DKUniversity of Copenhagen · DKHerlev Hospital · DK

Funding

Kræftens Bekæmpelse R149-A10159-B120Kræftens Bekæmpelse R90-A6143-14-S2
6 · The paper itself

Abstract

There is mounting evidence that the immune system can spontaneously clear malignant lesions before they manifest as overt cancer, albeit this activity has been difficult to demonstrate in humans. The calreticulin (CALR) exon 9 mutations are driver mutations in patients with chronic myeloproliferative neoplasms (MPN), which are chronic blood cancers. The CALR mutations generate a neo-antigen that is recognized by patient T cells, and T cells isolated from a patient with a CALR-mutation can recognize and kill autologous CALR-mutant cells. Surprisingly, healthy individuals display frequent and strong T cell responses to the CALR neo-antigens too. Furthermore, healthy individuals display immune responses to all parts of the mutant CALR epitope, and the CALR neo-epitope specific responses are memory T cell responses. These data suggest that although healthy individuals might acquire a CALR mutation, the mutant cells can be eliminated by the immune system. Additionally, a small fraction of healthy individuals harbor a CALR exon 9 mutation. Four healthy individuals carrying CALR mutations underwent a full medical examination including a bone marrow biopsy after a median follow up of 6.2 years. None of these patients displayed any signs of CALR-mutant MPN. Additionally, all healthy individuals displayed strong CALR neo-epitope specific T cell responses suggesting that these healthy individuals retained their CALR-mutant cells in the editing stage for several years. Thus, we suggest that CALR-mutant MPN could be a disease model of cancer immuno-editing, as we have demonstrated that CALR-mutant MPN displays all three stages described in the theory of cancer immuno-editing.

Indexed as

Disease SusceptibilityImmunomodulationTumor EscapeAnimalsAntigens, NeoplasmBiomarkers, TumorCalreticulinCell Transformation, NeoplasticDisease Models, AnimalEpitopesHematologic NeoplasmsHumansMutationAntigens, NeoplasmBiomarkers, TumorCalreticulinCALR protein, humanEpitopesCALRCITIM 2019Immuno-editingMyeloproliferative neoplasmsNeo-antigenT cell memory

Identifiers

PMID31915854
PMCPMC11027882
OpenAlexW2999133191

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.